Long-term PERSEUS results confirm sustained benefit of daratumumab-based therapy in newly diagnosed multiple myeloma

Daratumumab and isatuximab show comparable efficacy in newly diagnosed multiple myeloma

Multilevel factors shaping blinatumomab delivery across diverse LMICs

Isa-VRd shows sustained benefit in transplant-ineligible newly diagnosed multiple myeloma

Acyclovir prophylaxis reduces varicella infections in children receiving intensive chemotherapy

Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma

The evolving treatment landscape in immune thrombocytopenia

First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML

Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups

Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure